Sarepta (SRPT) PT Raised to $72 at Wedbush Ahead of US Launch of Exondys 51
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $72.00 (from $66.00) ahead of the US Launch of Exondys 51.
Behanna commented, "With the first patient dosed with commercial Exondys 51 this week, we have built out our model to look at US potential penetration into each segment of boys amenable to therapy – younger boys, ambulant boys and nonambulant boys. We have adjusted our 2016 revenue down to $4.8M, but increased peak revenues to $439M from $420M assuming that by 2022, over 1000 boys, or ~80% of genotyped patients in the US, will be on therapy. We see recent concerns on reimbursement as overdone and believe that case by case, near all boys will be covered. We continue to like shares of Sarepta ahead of full Exondys 51 launch, and clarity on an EU regulatory path."
The believes the launch should have a rapid start, but logistical challenges remain. "In our view, there is near unprecedented awareness of Exondys 51 and we expect many families to be queued up for drug. However, we believe 4Q sales will be modest, as it could take 30-90 days for reimbursement and we believe it will take time for boys to schedule appointments for infusion. Although home infusions could be an option over time, we anticipate all boys will go to hospitals for infusions at the start, translating into a 23.1% discount across the board."
Shares of Sarepta Therapeutic closed at $57.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt Upgrades NETGEAR (NTGR) to Buy
- Jefferies Cuts Price Target on W.R. Grace & Co. (GRA); Reiterates Buy
- PAREXEL (PRXL) PT, Estimates Lowered at Evercore ISI
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!